Bispecific Antibody Development for Breast Cancer

Bispecific antibodies (bsAbs) have emerged as a revolutionary approach in the treatment of breast cancer, particularly due to their ability to simultaneously target two different antigens. Breast cancer, with its diverse subtypes and complex biology, presents unique challenges that bsAbs aim to address by improving immune response and overcoming resistance to conventional therapies. Alfa Cytology specializes in the development of bispecific antibodies tailored for breast cancer therapy.

Introduction to Bispecific Antibody

Bispecific antibodies (BsAb ) are a class of engineered antibodies that combine the specific binding domains of two different mAb's into a single molecule, which allows them to interact with two different targets simultaneously, facilitating a variety of therapeutic strategies. BsAb have emerged as a promising approach for the treatment of Breast Cancer (BC), providing unique functionality for both targeted therapy and immunomodulation. This function targets tumor-associated antigens (TAA) on BC cells while engaging immune effector cells or blocking key signaling pathways. Several preclinical and clinical studies have demonstrated the potential of BsAb in BC therapy. For example, BsAb targeting HER2 has been shown to redirect immune cells to HER2-positive BC cells, resulting in effective tumor cell killing.

Fig.1 Three types of BsAb. (Lan HR, et al., 2023)

Bispecific Antibody Development for Breast Cancer

In breast cancer, the ability to target both tumor cells and immune cells is particularly compelling. For example, bsAbs can be designed to bind to cancer cell antigens, such as HER2, while simultaneously engaging T cell receptors to activate the immune response against the tumor. This mechanism has the potential to overcome some of the limitations associated with traditional monoclonal antibodies, providing a more effective approach in combating various breast cancer subtypes.

Our Services

Alfa Cytology has extensive expertise and experience in recombinant antibody production, providing fast and efficient bispecific antibody expression services. Utilizing optimized and proven expression platforms, production can begin from antibody sequences and facilitate the expression of multiple bispecific antibody formats.

We provide bispecific antibodies of different structures to meet the different needs of customers:

• CrossMAb
  CrossMAb technology reduces light chain mismatches and is often used in combination with other formats such as KiH, DEEK and ART-Ig. This method promotes the correct assembly of bispecific antibody (bsAb) light chains by exchanging heavy and light chain regions on one side.
• DutaMab
  DutaMab is designed with a variable region that recognizes two unrelated antigens. This is achieved through two binding sites (paratopes) on the antibody, taking advantage of the diversity of only three complementarity-determining regions per antigen.
• DVD-IgG
  DVD-IgG is formed from two parent monoclonal antibodies. Instead of using just one variable domain, two variable domains from one parent antibody are fused to the heavy and light chains of the other parent antibody.

Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC bispecific antibody development services and help in the development of therapies and diagnostics for BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.